Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

被引：0

作者：

Kagawa, Y. ^{[1
]}

Satake, H. ^{[2
]}

Kato, T. ^{[3
]}

Oba, K. ^{[4
]}

Yasui, H. ^{[5
]}

Nakamura, M. ^{[6
]}

Watanabe, T. ^{[7
]}

Hirata, K. ^{[8
]}

Muro, K. ^{[9
]}

Komatsu, Y. ^{[10
]}

Yoshino, T. ^{[11
]}

Yamazaki, K. ^{[12
]}

Mishima, H. ^{[13
]}

Kotaka, M. ^{[14
]}

Tsuji, A. ^{[15
]}

Kakeji, Y. ^{[16
]}

Oki, E. ^{[17
]}

Nagata, N. ^{[18
]}

Junichi, S. ^{[19
]}

机构：

[1] Kansai Rosai Hosp, Surg, Amagasaki, Hyogo, Japan

[2] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan

[3] Osaka Natl Hosp, Natl Hosp Org, Surg, Osaka, Japan

[4] Univ Tokyo, Dept Biostat, Tokyo, Japan

[5] Gen Hosp, Kobe City Med Ctr, Dept Med Oncol, Kobe, Hyogo, Japan

[6] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[7] Himeji Hosp, Japanese Red Cross Soc, Dept Surg, Himeji, Hyogo, Japan

[8] Univ Occupat & Environm Hlth, Dept Surg, Kitakyushu, Japan

[9] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan

[11] Natl Canc Ctr Hosp, Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Shizuoka Canc Ctr, Dept GI Oncol, Shizuoka, Japan

[13] Aichi Med Univ, Dept Surg, Nagakute, Aichi, Japan

[14] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan

[15] Kagawa Univ, Fac Med, Grad Sch Med, Dept Clin Oncol, Takamatsu, Kagawa, Japan

[16] Kobe Univ, Grad Sch Med, Dept Surg, Div Gastrointestibal Surg, Kobe, Hyogo, Japan

[17] Kyushu Univ Hosp, Dept Surg, Fukuoka, Fukuoka, Japan

[18] Kitakyushu Gen Hosp, Dept Surg, Kitakyushu, Fukuoka, Japan

[19] Tokai Cent Hosp, Kakamigahara, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

107P

引用

页数：2

共 50 条

[31] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
Cecchini, Michael
Kortmansky, Jeremy S.
Cui, Can
Wei, Wei
Thumar, Jaykumar Ranchobdhai
Uboha, Nataliya, V
Hafez, Navid
Lacy, Jill
Fischbach, Neal A.
Sabbath, Kert D.
Gomez, Christina M.
Sporn, Jonathan Reed
Stein, Stacey
Hochster, Howard S.
CANCER, 2021, 127 (09) : 1417 - 1424
[32] Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
Sun, Yongkun
Zhang, Jing
Wu, Guifu
Zhong, Xiaomin
Zhang, Wen
Liang, Ping
Li, Baoqi
Cui, Chengxu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 155 - 155
[33] A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
Lee, Valerie
Parkinson, Rose
Zahurak, Marianna
Cope, Leslie
Cercek, Andrea
Verheul, Henk
Gootjes, Elske
Lenz, Heinz Josef
Iqbal, Syma
Jones, Peter
Baylin, Stephen
Rami, Vandna
Ahuja, Nita
El Khoueiry, Anthony
Azad, Nilofer S.
INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (10) : 1794 - 1801
[34] A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Patel, Manish R.
Bendell, Johanna C.
Mayer, Robert J.
Benedetti, Fabio M.
Rosen, Lee S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[35] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
Kamiyama, H.
Yoshida, Y.
Yoshida, H.
Kosugi, C.
Ishibashi, K.
Ihara, K.
Takahashi, M.
Kuramochi, H.
Fukazawa, A.
Sonoda, H.
Yoshimatsu, K.
Matsuda, A.
Yamaguchi, S.
Ishida, H.
Hasegawa, S.
Yamada, T.
Sakamoto, K.
Koda, K.
ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
[36] A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302)
Coveler, Andrew L.
Kazmi, Farasat
Ciombor, Kristen Keon
Graham, Janet
Rodgers, Lisa Jane
Myers, Michelle
Berlin, Jordan
Blagden, Sarah Patricia
Evans, Jeffry T. R.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[37] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
Hisamatsu, A.
Ikusue, T.
Toshima, H.
Kobayashi, K.
Shimada, K.
ANNALS OF ONCOLOGY, 2019, 30
[38] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
Zhang, Jing
Yang, Wenwei
Liu, Junbao
Wang, Nan
Ren, Zhaoying
Yang, Tingting
Xie, Gongli
Wu, Guifu
Sun, Yongkun
INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
[39] A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410
Kuboki, Yasutoshi
Nishina, Tomohiro
Yamaguchi, Kensei
Shinozaki, Eiji
Komatsu, Yoshito
Yuki, Satoshi
Yamazaki, Kentaro
Hara, Hiroki
Fukutani, Miki
Uchida, Yasue
Tsukahara, Natsuko
Hasegawa, Hiromi
Matsuda, Seiko
Okamoto, Wataru
Yonemura, Masahito
Nomura, Shogo
Sato, Akihiro
Ohtsu, Atsushi
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
Conti, Matteo
Bolzacchini, Elena
Luchena, Giovanna
Bertu', Lorenza
Tagliabue, Paola
Aglione, Stefania
Ardizzoia, Antonio
Arnoffi, Jessica
Guida, Francesco Maria
Bertolini, Alessandro
Pastorini, Alessandro
Duro, Maria
Bettega, Donato
Roda', Giovambattista
Artale, Salvatore
Squizzato, Alessandro
Giordano, Monica
CANCERS, 2023, 15 (13)

← 1 2 3 4 5 →